ANALISE DOS INIBIDORES SELETIVOS DA RECAPTAÇÃO DE SEROTONINA COMO TRATAMENTO DE PRESSÃO NA ATENÇÃO BÁSICA: UMA REVISÃO DE LITERATURA
ANALISE DOS INIBIDORES SELETIVOS DA RECAPTAÇÃO DE SEROTONINA COMO TRATAMENTO DE PRESSÃO NA ATENÇÃO BÁSICA: UMA REVISÃO DE LITERATURA
-
DOI: https://doi.org/10.22533/at.ed.7622414053
-
Palavras-chave: Atenção primária; inibidor seletivo da receptação da serotonina; tratamento.
-
Keywords: Primary care; selective serotonin reuptake inhibitors; treatment.
-
Abstract: The evidence presented in the reviewed studies suggests that selective serotonin reuptake inhibitors (SSRIs) play a crucial role in the treatment of depression in primary care. The efficacy and safety of these medications make them a common choice for many patients, but the variation in treatment response highlights the need for a more personalized approach. Analysis of patients' clinical, neurobiological, and socioeconomic characteristics can help identify predictive factors that guide treatment choice and improve clinical outcomes. The reviewed studies emphasize the importance of a comprehensive initial assessment of patients with depression, including consideration of factors such as symptom severity, history of response to previous medications, presence of comorbid psychiatric disorders, and socioeconomic measures. Early identification of anxious symptoms and assessment of initial treatment response have also emerged as significant predictors of outcomes. Additionally, the inclusion of biomarkers, such as objective measures of EEG, may improve the ability to predict response to treatment with SSRIs. Analysis of specific EEG characteristics, such as neural activity frequencies and topological features, has been shown to add value to predicting improvement in depressive symptoms, especially in symptoms such as sleep difficulties, weight loss, agitation, and worry. However, it is important to recognize the limitations of the studies, such as the use of retrospective analyses and limited datasets. Addressing issues such as the placebo effect and the need to validate models across different types of antidepressant treatment are topics that should be addressed in future research. In conclusion, SSRIs continue to play a fundamental role in the treatment of depression in primary care, but the ideal approach should consider the individuality of each patient. The integration of biomarkers and predictive factors can improve the accuracy of predicting treatment response, enabling a more personalized and effective approach to managing depression. These findings have the potential to inform more effective clinical practices and improve outcomes for patients with depression in primary care.
- Stefany Campos Neves
- Natalia Barreto e Sousa